Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
نویسندگان
چکیده
منابع مشابه
Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEPNETs). However, there are some pitfalls that should be taken into consideration when evaluating the treatment response after PRRT. 354 Dutch patients with GEPNETs who were treated with 177Lu...
متن کاملResponse and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
UNLABELLED Peptide receptor radionuclide therapy (PRRT) is an efficient treatment for gastroenteropancreatic neuroendocrine tumors (GEP NETs), with outstanding overall response rates and survival. However, little is known about the particular efficacy regarding bone metastasis (BM). METHODS We retrospectively analyzed a consecutive subgroup of 42 patients with BM of GEP NETs treated with PRRT...
متن کاملγ-H2AX foci in peripheral blood lymphocytes to quantify radiation-induced DNA damage after 177Lu-DOTA-octreotate peptide receptor radionuclide therapy.
The paper by Denoyer et al. in the current issue of The Journal of Nuclear Medicine (1) explores the possibility of quantifying radiation-induced DNA damage after internal treatment with 177Lu-DOTA-octreotate (LuTate) peptide receptor radionuclide therapy for metastatic or inoperable neuroendocrine tumors. Radiation-induced DNA damage was quantified by analyzing the kinetics of phosphorylated h...
متن کاملPeptide receptor radionuclide therapy.
On their plasma membranes, cells express receptor proteins with high affinity for regulatory peptides, such as somatostatin. Changes in the density of these receptors during disease, for example, overexpression in many tumors, provide the basis for new imaging methods. The first peptide analogues successfully applied for visualization of receptor-positive tumors were radiolabeled somatostatin a...
متن کاملDose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
UNLABELLED Peptide receptor radionuclide therapy (PRRT) is a promising treatment for patients with neuroendocrine tumors, giving rise to improved survival. Dosimetric calculations in relation to PRRT have been concentrated to normal organ dosimetry in order to limit side effects. However, the relation between the absorbed dose to the tumor and treatment response has so far not been established....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Nuclear Medicine
سال: 2013
ISSN: 0161-5505,2159-662X
DOI: 10.2967/jnumed.112.119347